NASDAQ: MXCT
Maxcyte Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their MXCT stock forecasts and price targets.

Forecast return on equity

Is MXCT forecast to generate an efficient return?

Company
-20.61%
Industry
17.56%
Market
75.07%
MXCT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MXCT forecast to generate an efficient return on assets?

Company
-17.68%
Industry
9.18%
MXCT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MXCT earnings per share forecast

What is MXCT's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.43
Avg 2 year Forecast
-$0.42

MXCT revenue forecast

What is MXCT's revenue in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
$37.7M-17.43%
Avg 2 year Forecast
$46.1M+1.1%
MXCT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MXCT revenue growth forecast

How is MXCT forecast to perform vs Medical Devices companies and vs the US market?

Company
-17.43%
Industry
2.54%
Market
8.75%
MXCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MXCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MXCT vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
MXCT$3.67N/AN/A
ZIMV$14.66$23.00+56.89%Buy
NNOX$6.28$11.00+75.16%Strong Buy
DCTH$11.43$21.50+88.10%Strong Buy
CVRX$14.79$16.40+10.89%Strong Buy

Maxcyte Stock Forecast FAQ

What is MXCT's earnings growth forecast for 2024-2025?

(NASDAQ: MXCT) Maxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 49.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.84%.

Maxcyte's earnings in 2024 is -$35,735,800.On average, 3 Wall Street analysts forecast MXCT's earnings for 2024 to be -$45,009,407, with the lowest MXCT earnings forecast at -$46,412,326, and the highest MXCT earnings forecast at -$43,247,849.

In 2025, MXCT is forecast to generate -$43,954,582 in earnings, with the lowest earnings forecast at -$48,521,977 and the highest earnings forecast at -$35,864,070.

If you're new to stock investing, here's how to buy Maxcyte stock.

What is MXCT's revenue growth forecast for 2024-2025?

(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of -17.43% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 2.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.75%.

Maxcyte's revenue in 2024 is $45,599,600.On average, 2 Wall Street analysts forecast MXCT's revenue for 2024 to be $3,971,418,309, with the lowest MXCT revenue forecast at $3,966,144,181, and the highest MXCT revenue forecast at $3,976,692,437.

In 2025, MXCT is forecast to generate $4,862,745,924 in revenue, with the lowest revenue forecast at $4,725,618,598 and the highest revenue forecast at $4,999,873,249.

What is MXCT's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: MXCT) forecast ROA is -17.68%, which is lower than the forecast US Medical Devices industry average of 9.18%.

What is MXCT's Earnings Per Share (EPS) forecast for 2024-2025?

(NASDAQ: MXCT) Maxcyte's current Earnings Per Share (EPS) is -$0.34. On average, analysts forecast that MXCT's EPS will be -$0.43 for 2024, with the lowest EPS forecast at -$0.44, and the highest EPS forecast at -$0.41. In 2025, MXCT's EPS is forecast to hit -$0.42 (min: -$0.46, max: -$0.34).

What is MXCT's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: MXCT) forecast ROE is -20.61%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.